Denver—For the minority of patients who develop significant immune-related adverse events (AEs) while taking checkpoint inhibitors, it is appropriate to intervene quickly by delaying treatment, adding corticosteroids or both.
As the indications for checkpoint inhibitors grow, pharmacists are in a position to ensure that the optimal benefit-to-risk ratio from these agents is preserved.
“Giving steroids does not affect the clinical outcomes from what we know so far, so it